Phase III PEG-Intron in HIV-infected Patients (Study P00738)
Status:
Completed
Trial end date:
2003-10-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, multicenter trial testing 2 doses of PEG-Intron,
1.0mcg/kg/week and 3.0mcg/kg/week in heavily treatment-experienced HIV-infected patients
compared to placebo. The study will evaluate the efficacy and safety of PEG-Intron when added
to stable optimized background antiretroviral therapy in this patient population.